Live feed08:00:00·4dPRReleaseCalidi Biotherapeutics Presents New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026CLDI· Calidi Biotherapeutics Inc.Health CareOriginal source
